ABSTRACT
A reduction in the synthesis of the neuromodulator histamine has been associated with Tourette's syndrome and obsessive-compulsive disorder. Symptoms of these disorders are thought to arise from a dysfunction or aberrant development ofcorticostriatal circuits. Here, we investigated how histamine affects developing corticostriatal circuits, both acutely and longer-term, during the first postnatal weeks, using patch-clamp and field recordings in mouse brain slices (C57Bl/6, male and female). Immunohistochemistry for histamine-containing axons reveals striatal histaminergic innervation by the second postnatal week, and qRT-PCR shows transcripts for H1, H2, and H3 histamine receptors in striatum from the first postnatal week onwards, with pronounced developmental increases in H3 receptor expression. Whole-cell patch-clamp recordings of striatal spiny projection neurons and histamine superfusion demonstrates expression of functional histamine receptors from the first postnatal week onwards, with histamine having diverse effects on their electrical properties, including depolarization of the membrane potential while simultaneously decreasing action potential output. Striatal field recordings and electrical stimulation of corticostriatal afferents revealed that histamine, acting at H3 receptors, negatively modulates corticostriatal synaptic transmission from the first postnatal week onwards. Last, we investigated effects of histamine on longer-term changes at developing corticostriatal synapses and show that histamine facilitates NMDA receptor-dependent LTP via H3 receptors during the second postnatal week, but inhibits synaptic plasticity at later developmental stages. Together, these results show that histamine acutely modulates developing striatal neurons and synapses and controls longer-term changes in developing corticostriatal circuits, thus providing insight into the possible etiology underlying neurodevelopmental disorders resulting from histamine dysregulation.SIGNIFICANCE STATEMENT Monogenic causes of neurologic disorders, although rare, can provide opportunities to both study and understand the brain. For example, a nonsense mutation in the coding gene for the histamine-synthesizing enzyme has been associated with Tourette's syndrome and obsessive-compulsive disorder, and dysfunction of corticostriatal circuits. Nevertheless, the etiology of these neurodevelopmental disorders and histamine's role in the development of corticostriatal circuits have remained understudied. Here we show that histamine is an active neuromodulator during the earliest periods of postnatal life and acts at developing striatal neurons and synapses. Crucially, we show that histamine permits NMDA receptor-dependent corticostriatal synaptic plasticity during an early critical period of postnatal development, which suggests that genetic or environmental perturbations of histamine levels can impact striatal development.
Subject(s)
Cerebral Cortex/growth & development , Cerebral Cortex/physiology , Corpus Striatum/growth & development , Corpus Striatum/physiology , Histamine/physiology , Neuronal Plasticity , Receptors, Histamine/physiology , Animals , Corpus Striatum/drug effects , Female , Histamine/administration & dosage , Male , Membrane Potentials , Mice, Inbred C57BL , Neural Pathways/growth & development , Neural Pathways/physiology , Receptors, Histamine H1/physiology , Receptors, Histamine H2/physiology , Receptors, Histamine H3/physiology , Synaptic TransmissionABSTRACT
The present study was conducted to evaluate the effect of histamine and to characterise its receptor subtypes in reticular groove (RG) smooth muscle of adult goats. The studies were done using floor and lip regions of RG. We used tension experiments on smooth muscle of RG isolated from adult goat for functional characterisation of H1 and H2 receptors. Western blotting and immunohistochemistry experiments were conducted for molecular characterisation of these receptors. Histamine evoked concentration-dependent contraction of isolated RG circular and longitudinal smooth muscle preparation. Pyrilamine antagonised the action of histamine. Histamine did not induce any relaxant effect on RG preparations. Additionally, cimetidine did not produce any significant effect on histamine-induced response. Non-selective histaminic receptor antagonist cyproheptadine attenuated the contraction response to histamine in the smooth muscle. Molecular characterisation and localisation of H1 and H2 receptor proteins confirmed the presence of these receptors in RG. It is most likely that histamine-induced contractile effect in RG smooth muscle of goats is mediated by H1 histaminic receptors.
Subject(s)
Goats/metabolism , Histamine/metabolism , Muscle, Smooth/physiology , Receptors, Histamine/physiology , Stomach, Ruminant/physiology , Animals , Blotting, Western , Cimetidine/pharmacology , Cyproheptadine/pharmacology , Dose-Response Relationship, Drug , Goats/anatomy & histology , Histamine H1 Antagonists/pharmacology , Histamine H2 Antagonists/pharmacology , Immunohistochemistry , Muscle Contraction/drug effects , Muscle Contraction/physiology , Pyrilamine/pharmacology , Receptors, Histamine/classification , Stomach, Ruminant/anatomy & histologyABSTRACT
The neural histaminergic system innervates the cerebellum, with a high density of fibers in the vermis and flocculus. The cerebellum participates in motor functions, but the role of the histaminergic system in this function is unclear. In the present study, we investigated the effects of intracerebellar histamine injections and H1, H2 and H3 receptor antagonist injections (chlorpheniramine, ranitidine, and thioperamide, respectively) and H4 receptor agonist (VUF-8430) on locomotor and exploratory behaviors in mice. The cerebellar vermis of male mice was implanted with guide cannula. After three days of recovery,the animals received microinjections of saline or histamine (experiment1), saline or chlorpheniramine (experiment 2), saline or ranitidine(experiment 3), saline or thioperamide (experiment 4), and saline or VUF-8430 (experiment 5) in different concentrations. Five minutes postinjection,the open field test was performed. The data were analyzed using one-way ANOVA and Duncan's post hoc test. The microinjections of histamine, ranitidine or thioperamide did not lead any behavioral effects at the used doses. In contrast, animals that received chlorpheniramine at the highest dose (0.16 nmol) and VUF-8430 at the highest dose (1.48 nmol)were more active in the open field apparatus, with an increase in the number of crossed quadrants, number of rearings and time spent in the central area of the arena, suggesting that chlorpheniramine and VUF-8430 modulates locomotor and exploratory behaviors in mice.
Subject(s)
Cerebellar Vermis/drug effects , Exploratory Behavior/drug effects , Histamine Agents/administration & dosage , Locomotion/drug effects , Microinjections/methods , Animals , Cerebellar Vermis/physiology , Cerebellum/drug effects , Cerebellum/physiology , Dose-Response Relationship, Drug , Exploratory Behavior/physiology , Guanidines/administration & dosage , Histamine Antagonists/administration & dosage , Locomotion/physiology , Male , Mice , Receptors, Histamine/physiology , Thiourea/administration & dosage , Thiourea/analogs & derivativesABSTRACT
The article analyzes the anatomy, morphological and neurochemical connections and functions of the brain histaminergic system, one of the leading systems in the mechanism maintaining wakefulness. The possibilities of histaminergic system modulating for the treatment of various sleep/wake cycle disorders are discussed. The data of clinical trials on the influence of the histamine H1 receptor antagonist doxylamine on sleep in healthy volunteers and patients with insomnia are considered. The evidence-based efficacy of the drug in sleep disorders is discussed.
Subject(s)
Histamine Antagonists , Receptors, Histamine , Sleep Initiation and Maintenance Disorders , Brain/physiology , Histamine , Histamine Antagonists/therapeutic use , Humans , Receptors, Histamine/drug effects , Receptors, Histamine/physiology , Sleep , Sleep Initiation and Maintenance Disorders/drug therapy , WakefulnessABSTRACT
Settlement is a rapid process in many marine invertebrate species, transitioning a planktonic larva into a benthic juvenile. In indirectly developing sea urchins, this ecological transition correlates with a morphological, developmental and physiological transition (metamorphosis) during which apoptosis is essential for the resorption and remodelling of larval and juvenile structures. While settlement is initiated by environmental cues (i.e. habitat-specific or benthic substrate cues), metamorphosis is regulated by developmental endocrine signals, such as histamine (HA), thyroid hormones (THs) and nitric oxide (NO). In the purple sea urchin, Strongylocentrotus purpuratus, we found that suH1R mRNA levels increase during larval development and peak during metamorphic competence. SuH1R positive cell clusters are prominently visible in the mouth region of sea urchin larvae, but the protein appears to be expressed at low levels throughout the larval arms and epidermis. SuH1R knock-down experiments in larval stages show that the function of suH1R is in inhibiting apoptosis. Our results therefore suggest that suH1R is regulating the metamorphic transition by inhibiting apoptosis. These results provide new insights into metamorphic mechanisms and have implications for our understanding of settlement and metamorphosis in the marine environment.
Subject(s)
Apoptosis/physiology , Larva/cytology , Receptors, Histamine/physiology , Strongylocentrotus purpuratus/growth & development , Animals , Ecosystem , Gene Knockdown Techniques , Metamorphosis, Biological/physiology , Receptors, Histamine/genetics , Seawater , Strongylocentrotus purpuratus/anatomy & histologyABSTRACT
BACKGROUND: Gastric motility is controlled by the autonomic and enteric nervous systems and by interstitial cells of Cajal (ICCs). Although histamine is known to be released from enterochromaffin-like cells in the gastric mucosa, its regulatory roles in gastric motility are still controversial. Therefore, we investigated the functional roles of histamine in gastric motility. METHODS: Stomach preparations from hamsters were used because the stomach of hamsters can be easily separated into the forestomach and the glandular stomach. A whole preparation of the stomach was mounted in a Magnus tube, and mechanical responses were recorded using a force transducer. KEY RESULTS: Exogenous application of histamine had little effect on contractile activity of the glandular stomach. In contrast, the monoamine evoked regular, periodic contractions in the forestomach. An H1 receptor agonist reproduced the contractile responses and an H1 receptor antagonist blocked histamine-evoked contractions. Atropine and tetrodotoxin did not affect the histamine-evoked contractions. Pretreatment with drugs that inhibit the activity of ICCs abolished the effects of histamine. CONCLUSION & INFERENCES: The findings suggest that histamine regulates gastric motility by acting on ICCs via H1 receptors in the hamster. The remarkable ability of histamine to induce rhythmic contractions would be useful for treatment of gastric dysmotility.
Subject(s)
Gastric Mucosa/physiology , Gastrointestinal Motility , Histamine/physiology , Interstitial Cells of Cajal/physiology , Muscle, Smooth/physiology , Animals , Cricetinae , Gastric Mucosa/drug effects , Gastrointestinal Motility/drug effects , Histamine/administration & dosage , Histamine Agonists/administration & dosage , Histamine Antagonists/administration & dosage , Interstitial Cells of Cajal/drug effects , Male , Mesocricetus , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Physical Stimulation , Receptors, Histamine/physiologyABSTRACT
Recent findings have reasserted the role of histamine in the regulation of memory consolidation first proposed in 1986 in an inhibitory avoidance task in rats. They indicate that histamine is indeed a major regulator of memory consolidation in various tasks, through H2 receptors in the dorsal hippocampus and through H3 receptors in the basolateral amygdala, depending on the task. In the object recognition task, the memory enhancing effect is mediated by the three receptors (H1, H2, H3) in the dorsal hippocampus. In social recognition, the consolidation effect is mediated by H2 receptors in both amygdala and dorsal hippocampus. Data have suggested, in addition, influences on retrieval; this has been best studied in the dorsal hippocampus in step-down inhibitory avoidance task. Depending on the recent history of the conditioned stimulus (i.e., whether it has been recently reinforced or not), histamine acts on hippocampal H1 receptors, facilitating retrieval, or on H2 receptors, inhibiting it.
Subject(s)
Brain/physiology , Histamine/physiology , Memory Consolidation/physiology , Amygdala/physiology , Animals , Avoidance Learning/physiology , Hippocampus/physiology , Receptors, Histamine/physiologyABSTRACT
Distributed neural networks in the brain sustain generation of wakefulness and two sleep states: non-REM sleep and REM sleep. These three behavioral states are jointly ingrained in a rhythmic sequence that constitutes the sleep-wakefulness cycle. This paper reviews and updates knowledge about the involvement of the histaminergic system in sleep-wakefulness cycle organization. Histaminergic neurons are exclusively located in the hypothalamic tuberomammillary nucleus, but are the source of a widespread projection system to many brain regions. Histamine neurons are active during waking, especially with high attention need, and remain silent in both non-REM and REM sleep. There have been described four metabotropic histamine receptors, of which H1R, H2R and H3R are present in the nervous system. H1R and H2R are mainly postsynaptic heteroreceptors, whereas H3R is thought to be mostly a presynaptic auto- and hetero-receptor. Histaminergic neurons are excited by hypocretinergic neurons and most of the arousing hypocretin effects are thought to depend on histaminergic actions. Interactions among histaminergic axons and cholinergic nuclei within forebrain and brainstem are particularly important for cortical activation. In contrast, histaminergic tuberomammillary neurons, similarly to other aminergic neurons in locus coeruleus or dorsal raphe nucleus, are inhibited by non-REM sleep-promoting neurons of the preoptic region. Further inhibitory actions on histamine neurons come from adenosine release on tuberomammillary region. Finally, histaminergic neurons inhibit REM-on hypothalamic neurons containing melanine-concentrating hormone, thus supporting a permissive role of tuberomammillary nucleus in REM sleep. Actually, knockout mice for histidine decarboxylase, the enzyme synthetizing histamine, show a significant REM sleep increase.
TITLE: Regulacion de las fases del ciclo vigilia-sueño por la histamina.Redes neurales distribuidas en el encefalo sustentan la generacion de la vigilia y dos estados de sueño: sueño no REM y sueño REM. Estos tres estados comportamentales se engranan conjuntamente en una secuencia regular que constituye el ciclo vigilia-sueño. Este trabajo revisa y actualiza el conocimiento sobre la implicacion del sistema histaminergico en la organizacion del ciclo vigilia-sueño. Las neuronas histaminergicas se localizan exclusivamente en el nucleo tuberomamilar hipotalamico, pero son el origen de proyecciones extensas a numerosas regiones encefalicas. Las neuronas histaminergicas estan activas durante la vigilia, especialmente con alta demanda atencional, y permanecen silentes en sueño no REM y sueño REM. Se han descrito cuatro receptores histaminergicos metabotropicos, de los cuales H1R, H2R y H3R estan presentes en el sistema nervioso. H1R y H2R son fundamentalmente heterorreceptores postsinapticos, mientras que se piensa que H3R es mayormente un auto y heterorreceptor presinaptico. Las neuronas histaminergicas son activadas por las neuronas hipocretinergicas y se cree que muchos de los efectos activadores de las hipocretinas se deben a acciones histaminergicas. Las interacciones entre los axones histaminergicos y los nucleos colinergicos en el prosencefalo y el troncoencefalo son particularmente importantes para la activacion cortical. Por el contrario, las neuronas histaminergicas tuberomamilares, al igual que otras neuronas aminergicas del locus coeruleus o del nucleo dorsal del rafe, son inhibidas por las neuronas del area preoptica promotoras de sueño no REM. Acciones inhibidoras adicionales sobre las neuronas histaminergicas proceden de la liberacion de adenosina en la region tuberomamilar. Finalmente, las neuronas histaminergicas inhiben a las neuronas hipotalamicas REM-on que contienen hormona concentradora de melanina, apoyando asi un papel permisivo del nucleo tuberomamilar en el sueño REM. De hecho, ratones deficientes para descarboxilasa de histidina, la enzima de sintesis de la histamina, muestran un aumento significativo de sueño REM.
Subject(s)
Histamine/physiology , Sleep/physiology , Wakefulness/physiology , Animals , Humans , Mice , Neurons/physiology , Receptors, Histamine/physiologyABSTRACT
The functional expression of H4 receptors (H4R) within neurons of the central nervous system has been recently reported, but their role is poorly understood. The present study aims to elucidate the role of neuronal H4R by providing the first description of the behavioural phenotype of H4R-deficient (H4R knockout, H4R-KO) mice. Mice lacking H4R underwent behavioural studies to evaluate locomotor activity, pain perception, anxiety, depression, memory and feeding behaviour. H4R-KO mice showed a significant increase in ambulation in an open field as well as in exploratory activity in the absence of any modification of motor coordination. The sensitivity of mutant mice to a thermal or a mechanical stimulus was identical to that of the wild type mice, but H4R-KO showed sensory hypersensitivity toward a condition of neuropathic pain. The lack of H4R is associated with the promotion of anxiety in the light-dark box test. H4R-KO mice showed an increased immobility time in the tail suspension test, experimental procedure used to evaluate the response of H4R deficient mice to a behavioural despair paradigm. Cognitive function parameters of H4R deficient mice, examined using the passive avoidance and the novel object recognition tests, were unaltered showing the lack of influence of H4R on working and recognition memory. Finally, H4R-deficient mice showed an orectic phenotype. These results illustrate that H4R modulates various neurophysiological functions such as locomotor activity, anxiety, nociception and feeding behaviour, confirming the importance of the integrity and functionality of neuronal H4R in the histaminergic regulation of neuronal functions.
Subject(s)
Behavior, Animal/physiology , Receptors, G-Protein-Coupled/physiology , Receptors, Histamine/physiology , Animals , Anxiety/physiopathology , Central Nervous System/physiology , Depression/physiopathology , Feeding Behavior/physiology , Male , Memory/physiology , Mice , Mice, Inbred C57BL , Mice, Knockout , Motor Activity , Neurons/physiology , Nociception/physiology , Phenotype , Receptors, G-Protein-Coupled/genetics , Receptors, Histamine/genetics , Receptors, Histamine H4ABSTRACT
The potential contributions of the brain histaminergic system in neurodegenerative diseases, and the possiblity of histamine-targeting treatments is attracting considerable interests. The histamine H3 receptor (H3R) is expressed mainly in the central nervous system, and is, consequently, an attractive pharmacological target. Although recently described clinical trials have been disappointing in attention deficit hyperactivity disorder (ADHD) and schizophrenia (SCH), numerous H3R antagonists, including pitolisant, demonstrate potential in the treatment of narcolepsy, excessive daytime sleepiness associated with cognitive impairment, epilepsy, and Alzheimer's disease (AD). This review focuses on the recent preclinical as well as clinical results that support the relevance of H3R antagonists for the treatment of cognitive symptoms in neuropsychiatric diseases, namely AD, epilepsy and SCH. The review summarizes the role of histaminergic neurotransmission with focus on these brain disorders, as well as the effects of numerous H3R antagonists on animal models and humans.
Subject(s)
Alzheimer Disease/drug therapy , Brain/drug effects , Epilepsy/drug therapy , Histamine Antagonists/therapeutic use , Receptors, Histamine H3/physiology , Schizophrenia/drug therapy , Animals , Brain/physiopathology , Clinical Trials as Topic , Disease Models, Animal , Histamine Antagonists/administration & dosage , Humans , Memory/drug effects , Receptors, Histamine/physiologyABSTRACT
Several lines of evidence suggest a regulatory role of histamine in circadian rhythms, but little is known about signaling pathways that would be involved in such a putative role. The aim of this study was to examine whether histamine mediates its effects on the circadian system through Hrh1 or Hrh3 receptors. We assessed both diurnal and free-running locomotor activity rhythms of Hrh1-/- and Hrh3-/- mice. We also determined the expression of Per1, Per2 and Bmal1 genes in the suprachiasmatic nuclei, several areas of the cerebral cortex and striatum under symmetric 24 h light-dark cycle at zeitgeber times 14 and 6 by using radioactive in situ hybridization. We found no differences between Hrh1-/- and wild type mice in the length, amplitude and mesor of diurnal and free-running activity rhythms as well as in expression of Per1, Per2 and Bmal1 genes in any of the examined brain structures. The amplitude of free-running activity rhythm of the Hrh3-/- mice was significantly flattened, whereas the expression of the clock genes in Hrh3-/- mice was similar to the wild type animals in all of the assessed brain structures. Therefore, the knockout of Hrh1 receptor had no effects on the circadian rhythm of spontaneous locomotion, and a knockout of Hrh3 receptor caused a substantial reduction of free-running activity rhythm amplitude, but none of these knockout models affected the expression patterns of the core clock genes in any of the studied brain structures.
Subject(s)
Circadian Rhythm/physiology , Motor Activity/physiology , Photoperiod , Receptors, Histamine/physiology , ARNTL Transcription Factors/genetics , Animals , Cerebral Cortex/metabolism , Circadian Rhythm/genetics , Corpus Striatum/metabolism , Female , Gene Expression/radiation effects , In Situ Hybridization , Male , Mice, Inbred C57BL , Mice, Knockout , Motor Activity/genetics , Period Circadian Proteins/genetics , Receptors, Histamine/deficiency , Receptors, Histamine/genetics , Running/physiology , Suprachiasmatic Nucleus/metabolismABSTRACT
Anxiety is an unpleasant physiological state in which an overreaction to a situation occurs. It has been suggested that different brain regions are involved in the modulation and expression of anxiety, including the amygdala, hippocampus, and frontal cortex. Dysfunction of neurotransmitters and their receptors can lead to many mood disorders like anxiety. There are evidences that dopamine plays an important role in anxiety modulation in different parts of the brain. Some evidence has shown that the mesolimbic, mesocortical and nigrostriatal dopaminergic system are involved in anxiety. Both dopamine D1 and D2 receptor mechanisms are important in mediating anxiety. The activity of dopaminergic system is modulated by several neurotransmitters, including glutamatergic neurons from the medial prefrontal cortex (mPFC), GABAergic fibers from the nucleus accumbens (NAc) as well as the ventral pallidum and cholinergic fibers from the pedunculopontine nucleus and the laterodorsal tegmental nucleus. Thus, changes in the glutamatergic, and GABAergic, as well as mediated transmission in the mesolimbic, mesocortical and nigrostriatal dopaminergic system may influence anxiety-like behavior.
Subject(s)
Anxiety/physiopathology , Dopamine/physiology , Animals , Cholinergic Neurons/physiology , Dopaminergic Neurons/physiology , Humans , Limbic System/cytology , Limbic System/physiology , Receptors, Cannabinoid/physiology , Receptors, Dopamine/physiology , Receptors, Glutamate/physiology , Receptors, Histamine/physiologySubject(s)
Histamine , Allergens , Animals , Basophils/drug effects , Basophils/immunology , Biomedical Research , Cardiovascular System , Circadian Rhythm , Cytokines/biosynthesis , Cytokines/blood , Cytoplasmic Granules/chemistry , Dendritic Cells/immunology , Endothelial Cells/physiology , Eosinophils/physiology , Europe , Food Hypersensitivity , Gastrointestinal Tract , Histamine/genetics , Histamine/immunology , Histamine/physiology , Histamine Antagonists/pharmacology , Humans , Hypersensitivity/immunology , Immunoglobulin G/blood , Immunotherapy , Mast Cells/ultrastructure , Mice , Nervous System , Neurogenesis , Receptors, Histamine/deficiency , Receptors, Histamine/genetics , Receptors, Histamine/physiology , Societies, Medical/organization & administration , SpainABSTRACT
Histamine is one of the best-characterized pruritogens in humans. It is known to play a role in pruritus associated with urticaria as well as ocular and nasal allergic reactions. Histamine mediates its effect via four receptors. Antihistamines that block the activation of the histamine H1receptor, H1R, have been shown to be effective therapeutics for the treatment of pruritus associated with urticaria, allergic rhinitis, and allergic conjunctivitis. However, their efficacy in other pruritic diseases such as atopic dermatitis and psoriasis is limited. The other histamine receptors may also play a role in pruritus, with the exception of the histamine H2receptor, H2R. Preclinical evidence indicates that local antagonism of the histamine H3receptor, H3R, can induce scratching perhaps via blocking inhibitory neuronal signals. The histamine H4receptor, H4R, has received a significant amount of attention as to its role in mediating pruritic signals. Indeed, it has now been shown that a selective H4R antagonist can inhibit histamine-induced itch in humans. This clinical result, in conjunction with efficacy in various preclinical pruritus models, points to the therapeutic potential of H4R antagonists for the treatment of pruritus not controlled by antihistamines that target the H1R.
Subject(s)
Histamine Antagonists/therapeutic use , Pruritus/drug therapy , Animals , Histamine/physiology , Humans , Receptors, Histamine/physiologyABSTRACT
Among brain structures receiving efferent projections from the histaminergic tuberomammillary nucleus is the pontine locus coeruleus (LC) involved in descending noradrenergic control of pain. Here we studied whether histamine in the LC is involved in descending regulation of neuropathic hypersensitivity. Peripheral neuropathy was induced by unilateral spinal nerve ligation in the rat with a chronic intracerebral and intrathecal catheter for drug administrations. Mechanical hypersensitivity in the injured limb was assessed by monofilaments. Heat nociception was assessed by determining radiant heat-induced paw flick. Histamine in the LC produced a dose-related (1-10µg) mechanical antihypersensitivity effect (maximum effect at 15min and duration of effect 30min), without influence on heat nociception. Pretreatment of LC with zolantidine (histamine H2 receptor antagonist), but not with pyrilamine (histamine H1 receptor antagonist), and spinal administration of atipamezole (an α2-adrenoceptor antagonist), prazosine (an α1-adrenoceptor antagonist) or bicuculline (a GABAA receptor antagonist) attenuated the antihypersensitivity effect of histamine. The histamine-induced antihypersensitivity effect was also reduced by pretreatment of LC with fadolmidine, an α2-adrenoceptor agonist inducing autoinhibition of noradrenergic cell bodies. Zolantidine or pyrilamine alone in the LC failed to influence pain behavior, while A-960656 (histamine H3 receptor antagonist) suppressed hypersensitivity. A plausible explanation for these findings is that histamine, due to excitatory action mediated by the histamine H2 receptor on noradrenergic cell bodies, promotes descending spinal α1/2-adrenoceptor-mediated inhibition of neuropathic hypersensitivity. Blocking the autoinhibitory histamine H3 receptor on histaminergic nerve terminals in the LC facilitates release of histamine and thereby, increases descending noradrenergic pain inhibition.
Subject(s)
Histamine/physiology , Hyperalgesia/physiopathology , Locus Coeruleus/physiology , Neuralgia/physiopathology , Adrenergic Neurons/physiology , Adrenergic alpha-1 Receptor Antagonists/pharmacology , Adrenergic alpha-2 Receptor Agonists/pharmacology , Animals , Benzothiazoles/pharmacology , Bicuculline/pharmacology , GABA-A Receptor Antagonists/pharmacology , Histamine H2 Antagonists/pharmacology , Hot Temperature , Imidazoles/pharmacology , Indans/pharmacology , Male , Phenoxypropanolamines/pharmacology , Physical Stimulation , Piperidines/pharmacology , Prazosin/pharmacology , Rats , Receptors, Adrenergic, alpha-1/physiology , Receptors, Adrenergic, alpha-2/physiology , Receptors, Histamine/physiology , Spinal Nerves/injuriesABSTRACT
INTRODUCTION: Histamine H4 receptor (H4R) has been shown to be involved in various inflammatory conditions. Ligands acting on H4R show therapeutic potential in various diseases. For the first time, the positive proof-of-concept clinical trials of the H4 antagonist JNJ39758979 have demonstrated this potential in histamine-induced pruritus. Besides role of H4R in inflammatory conditions, preclinical results in cancer, neuropathic pain, vestibular disorders and type 2 diabetes show the diverse signaling network modulated by H4R. This suggests further potential for H4 ligands in such diseases. AREAS COVERED: In this review, we have summarized patent applications and papers of the H4R field published between 2012 and 2014. Additionally, we have analyzed the quality of the already described H4 ligands in terms of their ligand efficiency, lipophilic ligand efficiency and lipophilicity-corrected ligand efficiency. EXPERT OPINION: We demonstrate that the number of published patent applications reached a maximum in 2009 and showed some decrease in the last few years. On the other hand, the field is still very lively, reflected by the numerous publications on novel potential therapeutic applications. The favorable property profile of H4 ligands in development shows promise for the upcoming human clinical trials.
Subject(s)
Histamine Antagonists/pharmacology , Histamine Antagonists/therapeutic use , Receptors, G-Protein-Coupled/drug effects , Receptors, Histamine/drug effects , Animals , Clinical Trials as Topic , Humans , Ligands , Patents as Topic , Receptors, G-Protein-Coupled/physiology , Receptors, Histamine/physiology , Receptors, Histamine H4ABSTRACT
Among the four different types of histamine receptors (H1-H4), H4R is predominantly expressed in immune cells and involved in immunomodulatory response. Here, in this study we determined the expression of H4R in human mast cells (HMC-1, LAD-2 and primary cord blood derived CD34+ human mast cells) and characterized its functional properties. Interestingly, we found that human mast cells responded to both histamine (natural ligand) and 4-methylhistamine (selective H4R agonist) for sustained intracellular calcium mobilization, degranulation and cytokine production. However, only histamine induced the release of cAMP, but 4-methylhistamine down regulates cAMP indicating that H4R mediates its effect through Gαi/o protein and H1R via Gαq protein. Furthermore, both histamine and 4-methylhistamine induced the production of cysteinyl leukotrienes and LTB4. Using human inflammation antibody array membrane, we found that H4R induced the expression of various inflammatory proteins, involving pro-inflammatory cytokines and chemokines and these are TGF-ß1, TNF-α, TNF-ß, PDGF-BB, TIMP-2, M-CSF, IP-10, IL-16, IL-6, IL-3, IL-10, MIP-1α, IL-1α, ICAM-1, Eotaxin-2, RANTES, IL-8, MCP-1, and IL-6sR. We also quantified the level of various inflammatory cytokines produced by human mast cells through H4R. It was observed that, the production level of Th2 cytokines IL-4(401.34 pg/ml), IL-5 (64.21 pg/ml) and IL-13 (1044 pg/ml) and classical proinflammatory cytokines IL-6 (221.27 pg/ml) and IL-1ß (34.24 pg/ml) and chemokines MCP-1(106 pg/ml) and IL-8 (818.32 pg/ml). Furthermore, activation of H4R caused the phosphorylation of ERK and PI3K in a time dependent manner. Taken together these data demonstrate that, the activation of H4R in human mast cells produced not only inflammatory mediators that are associated with allergic reactions but also other inflammatory conditions.
Subject(s)
Mast Cells/immunology , Receptors, G-Protein-Coupled/physiology , Receptors, Histamine/physiology , Cells, Cultured , Cytokines/metabolism , Gene Expression , Humans , Immune System/metabolism , Infant, Newborn , Inflammation Mediators/metabolism , Leukotrienes/metabolism , Methylhistamines/metabolism , Receptors, G-Protein-Coupled/metabolism , Receptors, Histamine/metabolism , Receptors, Histamine H1/genetics , Receptors, Histamine H1/metabolism , Receptors, Histamine H4 , Th1 Cells/metabolism , Th2 Cells/metabolismABSTRACT
Histamine receptors are expressed on bone cells and histamine may be involved in regulation of bone metabolism. The aim of the present study was to investigate the effects of loratadine (an H(1) receptor antagonist), ranitidine (an H(2) receptor antagonist) and betahistine (an H(3) receptor antagonist and H(1) receptor agonist) on bone mechanical properties in rats. Loratadine (5 mg/kg/day, po), ranitidine (50 mg/kg/day, po), or betahistine dihydrochloride (5 mg/kg/day, po), were administered for 4 weeks to non-ovariectomized and bilaterally ovariectomized (estrogen-deficient) 3-month-old rats, and their effects were compared with appropriate controls. Serum levels of bone turnover markers, bone mineralization and mechanical properties of the proximal tibial metaphysis, femoral diaphysis and femoral neck were studied. In rats with normal estrogen level, administration of loratadine slightly favorably affected mechanical properties of compact bone, significantly increasing the strength of the femoral neck (p < 0.05), and tending to increase the strength of the femoral diaphysis. Ranitidine did not significantly affect the investigated parameters, and betahistine decreased the strength of the tibial metaphysis (cancellous bone, p < 0.01). There were no significant effects of the drugs on serum bone turnover markers. In estrogen-deficient rats, the drugs did not significantly affect the investigated skeletal parameters. In conclusion, the effects of histamine H(1), H(2) and H(3) receptor antagonists on the skeletal system in rats were differential and dependent on estrogen status.
Subject(s)
Bone and Bones/drug effects , Receptors, Histamine/physiology , Animals , Betahistine/pharmacology , Biomechanical Phenomena/drug effects , Bone Remodeling/drug effects , Bone and Bones/physiology , Calcification, Physiologic/drug effects , Female , Loratadine/pharmacology , Ovariectomy , Ranitidine/pharmacology , Rats , Rats, Wistar , Signal Transduction/physiologyABSTRACT
In the intestine of patients suffering from inflammatory bowel disease concentrations of histamine are increased compared to healthy controls. Genetic ablation of histamine production in mice ameliorates the course of experimentally induced colitis. These observations and first pharmacological studies indicate a function of histamine in the pathogenesis of inflammatory bowel disease. However, a closer examination reveals that available data are highly heterogeneous, limiting the rational design of strategies addressing specific histamine receptor subtypes as possible target for pharmacological interaction. However, very recently first clinical data indicate that antagonism at the histamine receptor subtype H4 provides a beneficial effect in at least the skin. Here, we discuss the available data on histamine effects and histamine receptor subtype functions in inflammatory bowel disease with a special emphasis on the histamine H4-receptor.
Subject(s)
Histamine/metabolism , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/physiopathology , Receptors, G-Protein-Coupled/metabolism , Receptors, Histamine/physiology , Animals , Colitis/metabolism , Colitis/pathology , Disease Models, Animal , Humans , Immune System/metabolism , Inflammatory Bowel Diseases/metabolism , Ligands , Mast Cells/drug effects , Mice , Rats , Receptors, Histamine/metabolism , Receptors, Histamine H4ABSTRACT
The histamine H4 receptor regulates the inflammatory response. However, it is not known whether this receptor has a functional role in human neutrophils. We found that fMLP (1 µM), but not histamine (0.1-1 µM), induced Mac-1-dependent adhesion, polarization, and degranulation (release of lactoferrin). A pretreatment of neutrophils with histamine (0.001-1 µM) or JNJ 28610244 (0.1-10 µM), a specific H4 receptor agonist, led to inhibition of degranulation. Total inhibition of degranulation was obtained with 0.1 µM histamine and 10 µM JNJ 28610244. Furthermore, such inhibition by histamine of degranulation was reversed by JNJ 7777120 and JNJ 28307474, two selective H4 receptor antagonists. However, neither histamine nor the H4 receptor agonist JNJ 28610244 prevented fMLP-induced, Mac-1-dependent adhesion, indicating that the H4 receptor may block signals emanating from Mac-1-controlling degranulation. Likewise, engagement of the H4 receptor by the selective agonist JNJ 28610244 blocked Mac-1-dependent activation of p38 MAPK, the kinase that controls neutrophil degranulation. We also show expression of the H4 receptor at the mRNA level in ultrapure human neutrophils and myeloid leukemia PLB-985 cells. We concluded that engagement of this receptor by selective H4 receptor agonists may represent a good, therapeutic approach to accelerate resolution of inflammation.